# 2025-02759: Thyroid Slim-Down Drugs Spark Epic Trade Violation Showdown

2025-02759, Certain Selective Thyroid Hormone Receptor-Beta Agonists, Processes for Manufacturing or Relating to Same, and Products Containing Same; Notice of a Commission Determination To Review a Final Initial Determination Finding a Violation of Section 337; Request for Written Submissions on Remedy, the Public Interest, and Bonding, is a Federal Register notice from International Trade Commission published 2025-02-19, effective 2025-02-19; PRIA reads it as touching household money (as of 2026-09-24).

- Canonical: https://policyrisk.com/federal-register/2025-02759
- As of: 2026-09-24
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-02759
- Title: Certain Selective Thyroid Hormone Receptor-Beta Agonists, Processes for Manufacturing or Relating to Same, and Products Containing Same; Notice of a Commission Determination To Review a Final Initial Determination Finding a Violation of Section 337; Request for Written Submissions on Remedy, the Public Interest, and Bonding
- Type: Notice
- Agencies: International Trade Commission
- Citation: 90 FR 9910
- Published: 2025-02-19
- Effective: 2025-02-19
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-24

## In one line

Thyroid Slim-Down Drugs Spark Epic Trade Violation Showdown

## Summary

The U.S. International Trade Commission is reviewing a decision that found a company violated trade rules involving special thyroid medicine ingredients. This affects Viking Therapeutics and others making or selling these products in the U.S. The Commission is now asking for input on how to fix the problem, protect the public, and handle money matters, with deadlines coming soon.

## Abstract

Notice is hereby given that the U.S. International Trade Commission ("Commission") has determined to review a final initial determination ("FID") issued by the presiding Chief Administrative Law Judge ("Chief ALJ"), finding a violation of section 337 of the Tariff Act of 1930, as amended. The Commission requests written submissions from the parties, interested government agencies, and other interested persons on the issues of remedy, the public interest, and bonding, under the schedule set forth below.

## Effects PRIA read

- Imported accused drugs could be barred: cost, high. The presiding judge recommended a seven-year limited exclusion order that could bar certain selective thyroid hormone receptor‑beta agonists and related products from entry into the United States. The statute authorizes the Commission to issue an exclusion order that would prevent the subject artic…
- Respondents may be ordered to stop U.S. sales: cost, medium. The recommended determination would also issue cease and desist orders requiring each respondent to stop engaging in unfair acts in the importation and sale of the accused articles in the United States. Cease and desist orders could prevent respondents from selling the accused products in the U.S.
- 100% bond could be required during review: cost, medium. The ALJ recommended imposing a 100 percent bond against accused articles imported during the period of Presidential review. If a remedy is ordered and the U.S. Trade Representative takes up to 60 days to act, the subject articles may enter the U.S. only under bond in an amount determined by the Com…
- Sanctions imposed on respondents and counsel: cost, medium. The final initial determination grants Viking's motion for sanctions under Commission Rule 210.33 and imposes certain non‑monetary and monetary sanctions against Respondents and/or their former counsel, Rimon PC, jointly and severally.
- Possible clinical‑trial import exemption considered: benefit, medium. The Commission specifically requested briefing on whether importation of accused products should be permitted for ongoing or planned clinical trials and asked parties to propose specific language and scope/duration if such an exemption is appropriate (citing 35 U.S.C. 271(e)(1)).
- Public interest review focused on NASH impacts: mixed, medium. The Commission will consider statutory public interest factors—public health and welfare, U.S. competitive conditions, U.S. production of like articles, and U.S. consumers—and requested detailed information about non‑alcoholic steatohepatitis (NASH), the effectiveness and availability of resmetirom…

## Related documents

- [2026-22911](https://policyrisk.com/federal-register/2026-22911): Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest, 2026-11-10
- [2026-22904](https://policyrisk.com/federal-register/2026-22904): Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest, 2026-11-10
- [2026-22923](https://policyrisk.com/federal-register/2026-22923): Prestressed Concrete Steel Wire Strand From China; Determinations, 2026-11-10
- [2026-22768](https://policyrisk.com/federal-register/2026-22768): Certain Glow Fish Tape Systems, Safety Helmet Systems, and Components Thereof; Notice of a Final Determination Finding a Violation of Secti…, 2026-11-09
- [2026-22730](https://policyrisk.com/federal-register/2026-22730): Certain Foundry Coke; Notice of a Commission Determination Not To Review an Initial Determination Granting Complainants' Motion To Amend th…, 2026-11-09
- [2026-22595](https://policyrisk.com/federal-register/2026-22595): Seamless Refined Copper Pipe and Tube From Vietnam; Scheduling of an Expedited Five-Year Review, 2026-11-05

## Sources
- [2025-02759 on federalregister.gov](https://www.federalregister.gov/documents/2025/02/19/2025-02759/certain-selective-thyroid-hormone-receptor-beta-agonists-processes-for-manufacturing-or-relating-to)
- [2025-02759 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-02-19/pdf/2025-02759.pdf)

## Related
- [Previous: 2025-02758, In the Matter of The Nasdaq Stock Market LLC; Order Granting Petition for Revie…](https://policyrisk.com/federal-register/2025-02758)
- [Next: 2025-02760, Methylene Diphenyl Diisocyanate (MDI) From China; Institution of Antidumping Du…](https://policyrisk.com/federal-register/2025-02760)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-02759 (as of 2026-09-24).
